At Janssen, our mission is to put the needs and well-being of the people we serve as a top priority. As part of the larger healthcare ecosystem, we also recognize our responsibility to listen to and learn from the medical community by working to address unmet needs and identifiable gaps in patient care by providing educational support to HCPs.
Pulmonary arterial hypertension (PAH) is a rare, progressive disease that causes narrowing of the arteries from the right side of the heart to the lungs, leading to high pressures in the arteries of the lungs.1-3 PAH currently has no known cure and can progress to right ventricular failure and death.1,5
For people living with this disease, risk assessment is utilized to evaluate disease progression and inform treatment decisions.5 While the need for timely and regular risk assessment in PAH is widely acknowledged, real-world evidence indicates that risk assessment in the clinical setting may be suboptimal; evidence suggests that some physicians encounter barriers to practical implementation, including the complexity of tools and invasive procedures.6,7
One of our goals is to help to raise awareness of screening and risk assessment in PAH. Recognizing a need to improve screening for PAH amongst an at-risk patient population, as well as a need for more timely and regular risk assessment for those living with PAH, 8 Janssen funded and supported the development of two tools: the REVEAL Lite 2 risk calculator and the DETECT Screening Tool app.